Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CFO James William Rogers sold 1,468 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $40.23, for a total value of $59,057.64. Following the transaction, the chief financial officer now directly owns 229,812 shares in the company, valued at $9,245,336.76. This represents a 0.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
James William Rogers also recently made the following trade(s):
- On Wednesday, December 11th, James William Rogers sold 83,025 shares of Tempus AI stock. The shares were sold at an average price of $42.30, for a total value of $3,511,957.50.
Tempus AI Trading Down 12.0 %
Shares of Tempus AI stock traded down $4.66 during trading on Wednesday, hitting $34.29. The stock had a trading volume of 7,396,915 shares, compared to its average volume of 1,521,735. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49. The company’s 50-day moving average price is $52.24.
Hedge Funds Weigh In On Tempus AI
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the stock. Piper Sandler reiterated a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital lifted their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Bank of America increased their target price on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Finally, Guggenheim assumed coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target for the company. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.
Get Our Latest Stock Report on TEM
About Tempus AI
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Articles
- Five stocks we like better than Tempus AI
- Canada Bond Market Holiday: How to Invest and Trade
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- What Are Dividend Challengers?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.